For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Connect with your Area Business Manager (ABM)

An ABM, your primary Sanofi Genzyme Representative, can help answer your questions and share the latest information about JEVTANA.

Please complete the form below or call Sanofi Genzyme at 800-633-1610 (option 5; option 1) and we will connect you with your local ABM.

  • Option 5: Calling to determine your sales representative

  • Option 1: Calling to determine your sales representative

All fields are required.






IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel